Suggested remit: To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating hypereosinophilic syndrome.
Status Awaiting development
Process MTA Review
ID number 3749

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
12 October 2020 - 09 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance